651 related articles for article (PubMed ID: 14734643)
1. Activation of toll-like receptor-9 induces progression of renal disease in MRL-Fas(lpr) mice.
Anders HJ; Vielhauer V; Eis V; Linde Y; Kretzler M; Perez de Lema G; Strutz F; Bauer S; Rutz M; Wagner H; Gröne HJ; Schlöndorff D
FASEB J; 2004 Mar; 18(3):534-6. PubMed ID: 14734643
[TBL] [Abstract][Full Text] [Related]
2. Viral double-stranded RNA aggravates lupus nephritis through Toll-like receptor 3 on glomerular mesangial cells and antigen-presenting cells.
Patole PS; Gröne HJ; Segerer S; Ciubar R; Belemezova E; Henger A; Kretzler M; Schlöndorff D; Anders HJ
J Am Soc Nephrol; 2005 May; 16(5):1326-38. PubMed ID: 15772251
[TBL] [Abstract][Full Text] [Related]
3. G-rich DNA suppresses systemic lupus.
Patole PS; Zecher D; Pawar RD; Gröne HJ; Schlöndorff D; Anders HJ
J Am Soc Nephrol; 2005 Nov; 16(11):3273-80. PubMed ID: 16176997
[TBL] [Abstract][Full Text] [Related]
4. Expression and regulation of Toll-like receptors in lupus-like immune complex glomerulonephritis of MRL-Fas(lpr) mice.
Patole PS; Pawar RD; Lech M; Zecher D; Schmidt H; Segerer S; Ellwart A; Henger A; Kretzler M; Anders HJ
Nephrol Dial Transplant; 2006 Nov; 21(11):3062-73. PubMed ID: 16954173
[TBL] [Abstract][Full Text] [Related]
5. Viral 5'-triphosphate RNA and non-CpG DNA aggravate autoimmunity and lupus nephritis via distinct TLR-independent immune responses.
Allam R; Pawar RD; Kulkarni OP; Hornung V; Hartmann G; Segerer S; Akira S; Endres S; Anders HJ
Eur J Immunol; 2008 Dec; 38(12):3487-98. PubMed ID: 19009528
[TBL] [Abstract][Full Text] [Related]
6. Bacterial CpG-DNA aggravates immune complex glomerulonephritis: role of TLR9-mediated expression of chemokines and chemokine receptors.
Anders HJ; Banas B; Linde Y; Weller L; Cohen CD; Kretzler M; Martin S; Vielhauer V; Schlöndorff D; Gröne HJ
J Am Soc Nephrol; 2003 Feb; 14(2):317-26. PubMed ID: 12538732
[TBL] [Abstract][Full Text] [Related]
7. Chemokine receptor Ccr2 deficiency reduces renal disease and prolongs survival in MRL/lpr lupus-prone mice.
Pérez de Lema G; Maier H; Franz TJ; Escribese M; Chilla S; Segerer S; Camarasa N; Schmid H; Banas B; Kalaydjiev S; Busch DH; Pfeffer K; Mampaso F; Schlöndorff D; Luckow B
J Am Soc Nephrol; 2005 Dec; 16(12):3592-601. PubMed ID: 16267157
[TBL] [Abstract][Full Text] [Related]
8. Correlation of renal tubular epithelial cell-derived interleukin-18 up-regulation with disease activity in MRL-Faslpr mice with autoimmune lupus nephritis.
Faust J; Menke J; Kriegsmann J; Kelley VR; Mayet WJ; Galle PR; Schwarting A
Arthritis Rheum; 2002 Nov; 46(11):3083-95. PubMed ID: 12428253
[TBL] [Abstract][Full Text] [Related]
9. Protective role for CCR5 in murine lupus nephritis.
Turner JE; Paust HJ; Bennstein SB; Bramke P; Krebs C; Steinmetz OM; Velden J; Haag F; Stahl RA; Panzer U
Am J Physiol Renal Physiol; 2012 Jun; 302(11):F1503-15. PubMed ID: 22442210
[TBL] [Abstract][Full Text] [Related]
10. Antagonist of monocyte chemoattractant protein 1 ameliorates the initiation and progression of lupus nephritis and renal vasculitis in MRL/lpr mice.
Hasegawa H; Kohno M; Sasaki M; Inoue A; Ito MR; Terada M; Hieshima K; Maruyama H; Miyazaki J; Yoshie O; Nose M; Fujita S
Arthritis Rheum; 2003 Sep; 48(9):2555-66. PubMed ID: 13130475
[TBL] [Abstract][Full Text] [Related]
11. Expression of natural autoantibodies in MRL-lpr mice protects from lupus nephritis and improves survival.
Mannoor K; Matejuk A; Xu Y; Beardall M; Chen C
J Immunol; 2012 Apr; 188(8):3628-38. PubMed ID: 22407922
[TBL] [Abstract][Full Text] [Related]
12. Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus.
Okazaki H; Hirata D; Kamimura T; Sato H; Iwamoto M; Yoshio T; Masuyama J; Fujimura A; Kobayashi E; Kano S; Minota S
J Rheumatol; 2002 Apr; 29(4):707-16. PubMed ID: 11950011
[TBL] [Abstract][Full Text] [Related]
13. Ligands to nucleic acid-specific toll-like receptors and the onset of lupus nephritis.
Pawar RD; Patole PS; Ellwart A; Lech M; Segerer S; Schlondorff D; Anders HJ
J Am Soc Nephrol; 2006 Dec; 17(12):3365-73. PubMed ID: 17082246
[TBL] [Abstract][Full Text] [Related]
14. Protection against autoimmune nephritis in MyD88-deficient MRL/lpr mice.
Sadanaga A; Nakashima H; Akahoshi M; Masutani K; Miyake K; Igawa T; Sugiyama N; Niiro H; Harada M
Arthritis Rheum; 2007 May; 56(5):1618-28. PubMed ID: 17469144
[TBL] [Abstract][Full Text] [Related]
15. Novel and enhanced IL-1 gene expression in autoimmune mice with lupus.
Boswell JM; Yui MA; Endres S; Burt DW; Kelley VE
J Immunol; 1988 Jul; 141(1):118-24. PubMed ID: 3259964
[TBL] [Abstract][Full Text] [Related]
16. CXCR3 mediates renal Th1 and Th17 immune response in murine lupus nephritis.
Steinmetz OM; Turner JE; Paust HJ; Lindner M; Peters A; Heiss K; Velden J; Hopfer H; Fehr S; Krieger T; Meyer-Schwesinger C; Meyer TN; Helmchen U; Mittrücker HW; Stahl RA; Panzer U
J Immunol; 2009 Oct; 183(7):4693-704. PubMed ID: 19734217
[TBL] [Abstract][Full Text] [Related]
17. Serum soluble MD-1 levels increase with disease progression in autoimmune prone MRL(lpr/lpr) mice.
Sasaki S; Nagai Y; Yanagibashi T; Watanabe Y; Ikutani M; Kariyone A; Tsuneyama K; Hirai Y; Takatsu K
Mol Immunol; 2012 Jan; 49(4):611-20. PubMed ID: 22118968
[TBL] [Abstract][Full Text] [Related]
18. Clear suppression of Th1 responses but marginal amelioration of autoimmune manifestations by IL-12p40 transgene in MRL-FAS(lprcg)/FAS(lprcg) mice.
Yasuda T; Yoshimoto T; Tsubura A; Matsuzawa A
Cell Immunol; 2001 Jun; 210(2):77-86. PubMed ID: 11520074
[TBL] [Abstract][Full Text] [Related]
19. Activated protein C attenuates systemic lupus erythematosus and lupus nephritis in MRL-Fas(lpr) mice.
Lichtnekert J; Rupanagudi KV; Kulkarni OP; Darisipudi MN; Allam R; Anders HJ
J Immunol; 2011 Sep; 187(6):3413-21. PubMed ID: 21849682
[TBL] [Abstract][Full Text] [Related]
20. (5R)-5-hydroxytriptolide ameliorates lupus nephritis in MRL/
Zhang LY; Li H; Wu YW; Cheng L; Yan YX; Yang XQ; Zhu FH; He SJ; Tang W; Zuo JP
Am J Physiol Renal Physiol; 2017 Apr; 312(4):F769-F777. PubMed ID: 28100505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
